(CS-112) A Case Series: Lyophilized Human Amnion Chorion Membrane (LHACM*) in the Treatment of Diabetic Foot Ulcers

Chronic wound rates continue to increase. Among Medicare beneficiaries, this increased from 14.5% in 2014 to 16.3% in 2019.¹ Diabetic foot ulcers (DFUs) affect 19% to 34% of patients with diabetes and continue to challenge clinicians.² Five-year mortality risk for patients with Charcot foot rivals the pooled all cancers risk and outnumbers the breast cancer five-year risk of mortality.³ In addition, the evidence is strong regarding the relationship between the number of comorbidities and risks for poor outcomes.⁴ 

Current recommended guidelines suggest that advanced therapies, including placental-based allografts, be considered for chronic wounds.^5-7 LHACM*, a new, novel tri-layer placental-based allograft intended for deeper and complex wounds, is presented in this case series.

Methods:

This case series includes five patients with chronic DFUs who were at high risk for morbidity and mortality, including amputation(s). They are all polymorbid with subsequent polypharmacy. LHACM* added to standard of care.

Results:

Five patients with chronic DFUs who were at high risk for morbidity and mortality, including amputation(s), were treated with LHACM* and their wounds closed.

Discussion: LHACM is a new, novel placental-derived product that is easy to handle and repositionable while dry or hydrated. It is shown to be effective in this case series in which very complicated patients with chronic DFUs were treated.